Welcome to the Pacific Edge Investor Centre. Here you will find useful information about being a shareholder of our company.
See the latest news and presentations, keep up to date with our newsletters and shareholder reports, find out when we are holding shareholder meetings and check up on our share price.
Pacific Edge is a publicly listed company on the NZX: listed as PEB.
- Value $00,000.000
- Volume 00,000
- Capitalisation $000,000
- Open $0.000
- Close $0.000
- High $0.000
- Low $0.000
Data up to date as of 00-00-0000 00:00
PEB Applies For Australian Stock Exchange (ASX) Dual Listing
Pacific Edge Limited will today lodge an application with the Australian Stock Exchange (ASX) to dual list as a Foreign Exempt Entity. Subject to the ASX accepting the application, PEB expects to be dual-listed on the ASX by the end of September 2021. [read more]
Journal of Urology Publishes Outperformance of Cxbladder in US Covid-19 Setting
The American Urological Association’s (AUA) Journal of Urology has published a real world lookback highlighting the clinical utility of Cxbladder in a Covid-19 setting for the management of patients outside the clinic. [read more]
Taranaki District Health Board Adopts Full Suite of Cxbladder Tests
Pacific Edge is pleased to confirm that the company has reached commercial agreement with Taranaki District Health Board (DHB) for the use of Cxbladder products across the clinical pathway in the detection, management, and monitoring of bladder cancer patients. [read more]
Reports and Presentations
For further investor information on Pacific Edge our recent annual reports, investor presentations and investment research reports are available for download below